

Appendix B

Clean copy of claims pending

1 1. (Amended) A conjugate comprising a drug coupled with an isolated peptide
2 sequence selected from the group consisting of SEQ ID Nos. 1-8.

1 2. (Amended) The conjugate of claim 1, said isolated peptide sequence having
2 from 4-30 amino acid residues.

1 6. The conjugate of claim 1, said drug selected from a class of drugs consisting of
2 anti-inflammatory agents, antitumor agent, oligonucleotides, cytokines, enzyme
3 inhibitors, and vasoregulator agents.

1 7. The conjugate of claim 1 said drug selected from the group consisting of
2 methotrexate, lovastatin, taxol, ajmalicine, vinblastine, vincristine, cyclophosphamide,
3 fluorouracil, idarubicin, ifosfamide, irinotecan, 6-mercaptopurine, mytomycins,
4 mitoxantrone, paclitaxel, taxol, pentostatin, plicamycin, topotecan, fludarabine,
5 etoposide, doxorubicin, doxotaxel, danorubicin, albuterol, and propidium.

1 8. The conjugate of claim 1, said drug being methotrexate.

1 9. (Amended) The conjugate of claim 1, said isolated peptide sequence having at
2 least about 50% homology with at least one of said SEQ ID Nos. 1-8.

1 35. The conjugate of claim 1, said conjugate characterized by the ability of
2 binding to surface receptors of target cells and subsequently being internalized by said
3 target cells.

1 37. (Amended) The conjugate of claim 1, wherein the a drug is coupled with an
2 isolated peptide sequence of SEQ ID NO. 8. wherein the peptide sequence further
3 comprises penicillamine.

1 38. The conjugate of claim 1, said isolated peptide sequence being cyclic.

1 42. A conjugate comprising a first portion and a second portion, wherein said first
2 portion is a peptide and said second portion is a drug, said peptide being derived from
3 ICAM-1 or LFA-1 and being characterized by binding to LFA-1 and ICAM-1 receptors
4 on leudocytes and by being internalized by cells expressing at least one of said receptors.